Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

Spleen Size Is Significantly Influenced by Body Height and Sex: Establishment of Normal Values for Spleen Size at US with a Cohort of 1200 Healthy Individuals.

Chow KU, Luxembourg B, Seifried E, Bonig H.

Radiology. 2016 Apr;279(1):306-13. doi: 10.1148/radiol.2015150887. Epub 2015 Oct 28.

PMID:
26509293
2.

Deferrals of volunteer stem cell donors referred for evaluation for matched-unrelated stem cell donation.

Bräuninger S, Thorausch K, Luxembourg B, Schulz M, Chow KU, Seifried E, Bonig H.

Bone Marrow Transplant. 2014 Nov;49(11):1419-25. doi: 10.1038/bmt.2014.171. Epub 2014 Aug 4.

PMID:
25089595
3.

Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator.

Stein J, Dignass A, Chow KU.

Curr Med Res Opin. 2012 Feb;28(2):241-3. doi: 10.1185/03007995.2011.651527. Epub 2012 Jan 18.

PMID:
22181342
4.

News on hypomethylating agents: chasing the FOX.

Chow KU.

Cell Cycle. 2011 Sep 15;10(18):3050. Epub 2011 Sep 15. No abstract available.

PMID:
21908975
5.

Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.

Chow KU, Kim SZ, von Neuhoff N, Schlegelberger B, Stilgenbauer S, Wunderle L, Cordes HJ, Bergmann L.

Eur J Haematol. 2011 Nov;87(5):426-33. doi: 10.1111/j.1600-0609.2011.01680.x. Epub 2011 Aug 23.

PMID:
21749447
6.

Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.

Boehrer S, Schroeder P, Mueller T, Atz J, Chow KU.

Anticancer Drugs. 2011 Jul;22(6):519-30. doi: 10.1097/CAD.0b013e328344887f.

PMID:
21637160
7.

[Gross haematuria as the primary symptom of extramedullary IgM plasmacytoma of the bladder].

Tsaur I, Probst M, Chow KU, Renne C, Cerovac I, Pelekanos C, Juengel E, Wedel SA, Bickeböller R, Karalis A.

Urologe A. 2010 Jul;49(7):850-4. doi: 10.1007/s00120-010-2293-9. German.

PMID:
20383630
8.

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.

Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS.

Leuk Lymphoma. 2010 Mar;51(3):447-55. doi: 10.3109/10428190903580402.

PMID:
20141439
9.

Inhibition of osteosarcoma cell proliferation by the Hedgehog-inhibitor cyclopamine.

Warzecha J, Göttig S, Chow KU, Brüning C, Percic D, Boehrer S, Brude E, Kurth A.

J Chemother. 2007 Oct;19(5):554-61.

PMID:
18073155
10.

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.

Müller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS.

Cancer Immunol Immunother. 2008 Mar;57(3):411-23. Epub 2007 Aug 24.

PMID:
17717662
11.

Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells.

Nowak D, Boehrer S, Hochmuth S, Trepohl B, Hofmann W, Hoelzer D, Hofmann WK, Mitrou PS, Ruthardt M, Chow KU.

Anticancer Drugs. 2007 Oct;18(9):981-95.

PMID:
17704648
12.

The tyrosine kinase inhibitor AMN107 (Nilotinib) exhibits off-target effects in lymphoblastic cell lines.

Chow KU, Nowak D, Trepohl B, Hochmuth S, Schneider B, Hoelzer D, Mitrou PS, Bergmann L, Ottmann OG, Boehrer S.

Leuk Lymphoma. 2007 Jul;48(7):1379-88.

PMID:
17613767
13.

Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.

Atta J, Chow KU, Weidmann E, Mitrou PS, Hoelzer D, Martin H.

Leuk Lymphoma. 2007 Feb;48(2):349-56.

PMID:
17325896
14.

Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer.

Friedmann I, Atmaca A, Chow KU, Jäger E, Weidmann E.

J Chemother. 2006 Aug;18(4):415-20.

PMID:
17024798
15.
16.

The molecular biology of TRAIL-mediated signaling and its potential therapeutic exploitation in hematopoietic malignancies.

Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU.

Curr Med Chem. 2006;13(18):2091-100. Review.

PMID:
16918339
17.

Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study.

Hentrich M, Maretta L, Chow KU, Bogner JR, Schürmann D, Neuhoff P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P.

Ann Oncol. 2006 Jun;17(6):914-9. Epub 2006 Mar 24.

PMID:
16565210
18.

Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis.

Boehrer S, Nowak D, Puccetti E, Ruthardt M, Sattler N, Trepohl B, Schneider B, Hoelzer D, Mitrou PS, Chow KU.

Leuk Res. 2006 May;30(5):597-605. Epub 2006 Mar 2.

PMID:
16513168
19.

Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies.

Boehrer S, Nowak D, Hoelzer D, Mitrou PS, Chow KU.

Curr Pharm Des. 2006;12(1):111-28. Review.

PMID:
16454729
20.

In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling.

Chow KU, Nowak D, Kim SZ, Schneider B, Komor M, Boehrer S, Mitrou PS, Hoelzer D, Weidmann E, Hofmann WK.

Pharmacol Res. 2006 Jan;53(1):49-61. Epub 2005 Oct 5.

PMID:
16213748

Supplemental Content

Support Center